[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349054-105":59,"doc-detail-349054-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","harnessing-a-bispecific-gd2-cd3-protein-engager-to-target-gd2-overexpressing-lung-tumors","Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors","","Lung cancer remains a leading cause of cancer death worldwide, driven by poor survival and frequent treatment resistance. Disialoganglioside GD2 is presented as a promising tumor-associated antigen for immunotherapy. The study confirms GD2 expression in lung cancer cells and builds a bispecific protein engager, αGD2 × αCD3 BiPE, to redirect T cells toward GD2-expressing targets. BiPE production and purification are verified by Western blot, while binding assays show specificity for GD2 and CD3. BiPE enhances T-cell activation, proliferation, and cytotoxicity, improving killing of GD2-high A549 cells versus GD2-low NCI-H460, demonstrating GD2-dependent anti-tumor activity and therapeutic potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-a-bispecific-gd2-cd3-protein-engager-to-target-gd2-overexpressing-lung-tumors/349054/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-a-bispecific-gd2-cd3-protein-engager-to-target-gd2-overexpressing-lung-tumors/349054.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study aim to address in lung cancer treatment?","Question",{"text":112,"@type":113},"It targets the challenge of poor survival and treatment resistance in lung cancer, emphasizing the need for more effective therapies that improve outcomes and reduce limitations of existing approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does αGD2 × αCD3 BiPE work in the proposed therapeutic strategy?",{"text":117,"@type":113},"It is designed to redirect T cells toward GD2-overexpressing lung cancer cells by simultaneously recognizing GD2 on tumor cells and CD3 on T cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What key experimental findings demonstrate BiPE effectiveness?",{"text":121,"@type":113},"BiPE specifically binds GD2 and CD3, enhances T-cell activation and proliferation after treatment, and increases T-cell cytotoxicity in co-culture, leading to greater killing of A549 cells than NCI-H460 cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349054,1790534821,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nHarnessing a bispecific  \nαGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors  \nNunghathai Sawasdee1,2, Aussara Panya3,4, Jatuporn Sujjitjoon1,2, Pa-thai Yenchitsomanus1,2 & Chutamas Thepmalee5􀀍  \nLung cancer remains one of the most prevalent and lethal malignancies worldwide, with persistently poor 5-year survival rates across all stages. The development of novel therapies is therefore crucial for overcoming treatment resistance, improving survival rates, reducing side effects, and enhancing patient outcomes. Disialoganglioside GD2 has emerged as an attractive tumor-associated antigen for immunotherapy against various cancer types. In our study, we confirmed GD2 expression in lung cancer cells and observed differential expression levels, with A549 cells exhibiting markedly higher GD2 expression compared to NCI-H460 cells. To specifically target GD2-expressing lung cancers, we engineered a bispecific protein engager, termed αGD2 × αCD3 BiPE, designed to redirect T cells toward GD2-overexpressing lung cancer cells. The αGD2 × αCD3 BiPE (55 kDa) was successfully produced ina eukaryotic expression system and purified, as confirmed by Western blot analysis. Binding assays demonstrated that the BiPE specifically recognized GD2 on 143B osteosarcoma cells (which exhibit high GD2 expression) and CD3 onT cells. Functionally, treatment with αGD2 × αCD3 BiPE significantly enhanced T-cell activation and proliferation, as indicated by increased proportion of CD25 + CD3+ and CD69 + CD3+ cells after 5 days compared with untreated controls. In co-culture experiments, the BiPE also enhanced T-cell cytotoxicity, resulting in greater killing of A549 cells compared to NCI-H460 cells, consistent with their differential GD2 expression. These findings demonstrate that αGD2 × αCD3 BiPE effectively enhancesT-cell activity and anti-tumor responses in a GD2-dependent manner. This study highlights its potential as a promising therapeutic strategy for GD2-overexpressing cancers, warranting further optimization and evaluation across diverse tumor types.  \nKeywords Lung cancer, Immunotherapy, GD2, Bispecific protein engager (BiPE), Biologics  \nLung cancer is one of the most common cancers worldwide and remains the leading cause of cancer-related death, with a steadily increasing incidence and mortality rate. Lung cancer is categorized into two major histologic subtypes: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) . NSCLC accounts for approximately 85–90% of all cases, which can be further categorized into adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma. According to GLOBOCAN 2022, an estimated 2.48 million (12.4%) new cases of lung cancer were reported globally across all subtypes1. In men, lung cancer accounted for 1.57 million cases, with adenocarcinoma being the most common subtype (45.6%), followed by squamous cell carcinoma (SCC, 29.4%), small-cell carcinoma (11.5%), and large-cell carcinoma (6.5%). Among women (908,630 cases), adenocarcinoma was also the predominant subtype (59.7%), followed by SCC (17.1%), small-cell carcinoma (9.7%), and large-cell carcinoma (6.5%)1.  \nThe incidence and mortality rate of lung cancer are influenced by a range of genetic and environmental factors. Somatic mutations in key oncogenes and tumor suppressor genes, such as TP53, EGFR, and KRAS, are  \n1Faculty of Medicine, Siriraj Hospital, Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORECIT), Mahidol University, Bangkok 10700, Thailand. 2Division of Molecular Medicine, Research Department, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. 3Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand. 4Cell Engineering for Cancer Therapy Research Group, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand. 5Division of Biochemistry, S","cbCaip8husad8Max","https://ap.wps.com/l/cbCaip8husad8Max","pdf",4591781,14,"English","# Introduction\n## Lung cancer burden and subtypes\n## Genetic and environmental factors\n## Current treatments and need for new strategies\n## Immunotherapy and rationale for BiPEs","[{\"question\":\"What problem does the study aim to address in lung cancer treatment?\",\"answer\":\"It targets the challenge of poor survival and treatment resistance in lung cancer, emphasizing the need for more effective therapies that improve outcomes and reduce limitations of existing approaches.\"},{\"question\":\"How does αGD2 × αCD3 BiPE work in the proposed therapeutic strategy?\",\"answer\":\"It is designed to redirect T cells toward GD2-overexpressing lung cancer cells by simultaneously recognizing GD2 on tumor cells and CD3 on T cells.\"},{\"question\":\"What key experimental findings demonstrate BiPE effectiveness?\",\"answer\":\"BiPE specifically binds GD2 and CD3, enhances T-cell activation and proliferation after treatment, and increases T-cell cytotoxicity in co-culture, leading to greater killing of A549 cells than NCI-H460 cells.\"}]","Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors | PDF",1790081418,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/567ec5050a52aee3a389f21a48e5a7d1.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76fd1baedc91a4926e34163bb7d8618b.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09834d4dae916ade1dc316acbda80d04.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b5e8a128314d84fd93d3521e69f3f4a.webp",980,1287]